GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

GAMMA Investing LLC raised its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 6,905.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,130 shares of the biopharmaceutical company's stock after buying an additional 176,573 shares during the quarter. GAMMA Investing LLC owned 0.11% of TG Therapeutics worth $7,063,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TGTX. Stratos Wealth Advisors LLC acquired a new stake in TG Therapeutics during the fourth quarter worth approximately $241,000. Choreo LLC acquired a new stake in TG Therapeutics during the fourth quarter worth about $247,000. Bleakley Financial Group LLC acquired a new position in shares of TG Therapeutics in the 4th quarter valued at approximately $245,000. Strategic Financial Concepts LLC bought a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $1,404,000. Finally, Empowered Funds LLC boosted its position in shares of TG Therapeutics by 6.1% during the 4th quarter. Empowered Funds LLC now owns 49,267 shares of the biopharmaceutical company's stock worth $1,483,000 after acquiring an additional 2,836 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded down $0.95 during mid-day trading on Thursday, hitting $37.37. 2,789,921 shares of the stock traded hands, compared to its average volume of 2,963,225. The company has a market cap of $5.93 billion, a PE ratio of -373.66 and a beta of 1.94. TG Therapeutics, Inc. has a twelve month low of $16.21 and a twelve month high of $46.48. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a 50 day simple moving average of $37.23 and a two-hundred day simple moving average of $34.78.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. During the same quarter in the prior year, the business posted ($0.07) earnings per share. TG Therapeutics's revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TGTX shares. HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.